The U.S. Supreme Court is poised to decide one of the most impactful intellectual property cases of our nation's history. The case involves a dispute between innovator companies, Amgen and Sanofi/Regeneron, that independently developed life-saving antibody therapeutics that reduce low-density lipoprotein (LDL) or "bad" cholesterol. Both antibodies treat thousands of patients with elevated cholesterol by binding to the same naturally occurring therapeutic target, PCSK9, and blocking it from interfering with LDL receptors that remove cholesterol from the blood.